-Bloomberg
Horizon Therapeutics Reports Results From New Analysis Of UPLIZNA Phase 2/3 Trial Showing A Correlation Between Depth Of B-Cell Depletion, Improved Neuromyelitis Optica Spectrum Disorder Patient Outcomes
-- Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity --
Horizon Therapeutics plc (NASDAQ:HZNP) today announced results from a new analysis of the